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Predictions of diabetes prevalence over the next decades warrant the aggressive discov-
ery of new approaches to stop or reverse loss of functional beta cell mass. Beta cells
are recognized to have a relatively high sensitivity to reactive oxygen species (ROS) and
become dysfunctional under oxidative stress conditions. New discoveries have identified
NADPH oxidases in beta cells as contributors to elevated cellular ROS. Reviewed are recent
reports that evidence a role for NADPH oxidase-1 (NOX-1) in beta cell dysfunction. NOX-
1 is stimulated by inflammatory cytokines that are elevated in diabetes. First, regulation
of cytokine-stimulated NOX-1 expression has been linked to inflammatory lipid mediators
derived from 12-lipoxygenase activity. For the first time in beta cells these data integrate
distinct pathways associated with beta cell dysfunction. Second, regulation of NOX-1 in
beta cells involves feed-forward control linked to elevated ROS and Src-kinase activation.
This potentially results in unbridled ROS generation and identifies candidate targets for
pharmacologic intervention.Third, consideration is provided of new, first-in-class, selective
inhibitors of NOX-1. These compounds could have an important role in assessing a disrup-
tion of NOX-1/ROS signaling as a new approach to preserve and protect beta cell mass in
diabetes.
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BETA CELL DYSFUNCTION
Beta cell dysfunction and loss of functional beta cell mass is a
principle contributor to the development of diagnosable diabetes.
Current therapeutic options do little to halt or reverse a loss of beta
cell function. There remains a clinical need to better understand
the events contributing to diminished beta cell function and to
develop new strategies for beta-cell preservation and protection.
As projected by the Centers for Disease Control and Prevention,
one in three adults in the United States of America could have
diabetes by 2050 (Boyle et al., 2010). In children (less than 20 years
of age), it is conservatively estimated that a 23% increase in type
1 diabetes and a 49% increase in type 2 diabetes will occur over
the next 40 years. Worryingly, this prevalence could increase more
than threefold with shifts in population demographics (Imper-
atore et al., 2012). Globally, a significant increase in worldwide
diabetes prevalence is projected1.
OXIDATIVE STRESS IN THE BETA CELL
Oxidative stress in the beta cell is recognized as a pathogenic step
leading to loss of beta cell function (Lenzen, 2008). Pancreatic islets
have been shown to express low activity of free-radical detoxifying
enzymes (e.g., catalase, superoxide dismutase, glutathione perox-
idase) when compared to other tissues (Grankvist et al., 1981;
Lenzen et al., 1996; Tiedge et al., 1997; Modak et al., 2007). Islets
are also very poor in rectifying oxidative damage to DNA (Modak
1International Diabetes Federation (http://www.idf.org/diabetesatlas/5e/the-
global-burden).
et al., 2009). Thus, under conditions of sustained activation of
intracellular reactive species, islets are readily overwhelmed and
undergo oxidative stress (Lenzen, 2008). Under oxidative stress
conditions, the elevated reactive oxygen species (ROS), in addition
to oxidizing proteins, lipids, and DNA, also activate stress-sensitive
second messengers such as p38MAPK, JNK (Purves et al., 2001),
and PKC (Koya and King, 1998). A consequence of JNK activation
is a translocation of the homeodomain transcription factor pdx-1
from the nucleus to the cytoplasm. PDX-1 is a key transactivator
of the insulin gene (Ohneda et al., 2000). As pdx-1 also transacti-
vates its own expression (Kawamori et al., 2003), the consequence
of cytoplasmic translocation of pdx-1 in conditions of oxidative
stress further limits insulin expression and contributes to beta cell
dysfunction. The beta cell therefore, has to orchestrate a delicate
balance in ROS generation. While on one hand an overstimula-
tion of ROS is destructive to beta cell function and survival, on the
other hand a transient increase in ROS generation is a required sec-
ond messenger for glucose-stimulated insulin secretion (Goldstein
et al., 2005; Pi et al., 2007; Newsholme et al., 2009). Reinforcing
this requirement, neutralization of ROS activity in beta cells with
anti-oxidants decreases the glucose-stimulated insulin response
(Morgan et al., 2009).
Serum conditions associated with the diabetic state, increased
pro-inflammatory cytokines, high free fatty acids (FFA), and ele-
vated glucose levels, are all potent inducers of elevated cellular
ROS (Janciauskiene and Ahren, 2000; Oliveira et al., 2003; Cun-
ningham et al., 2005; Inoguchi and Nawata, 2005; Nakayama et al.,
2005; Uchizono et al., 2006; Morgan et al., 2007; Michalska et al.,
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2010). Inflammation and elevation in pro-inflammatory cytokines
is an established feature of type 1 diabetes (Eizirik and Mandrup-
Poulsen, 2001; Jorns et al., 2005), and in recent studies low-grade
chronic inflammation and an increase in serum pro-inflammatory
cytokines have been recognized as key features of type 2 diabetes
(Catalan et al., 2007; Steinberg, 2007; Tilg and Moschen, 2008;
Al-Maskari et al., 2010; Igoillo-Esteve et al., 2010; Kang et al.,
2010; Su et al., 2010). Within the beta cell, cellular sources of ROS
originate from induced mitochondrial stress (reviewed in New-
sholme et al., 2007) and endoplasmic reticulum stress (reviewed
in Volchuk and Ron, 2010). While these have been considered
the main sources of ROS in pancreatic islets, identification of
NADPH oxidase complexes in beta cells have brought the issue
of the relative contribution to ROS generation under debate.
NOX FAMILY OF NADPH OXIDASES
NOX family of NADPH oxidases are proteins that transfer elec-
trons across biological membranes (plasma or organelle). Their
function is the generation of ROS, superoxide, and hydrogen
peroxide (H2O2). The phagocyte NADPH oxidase was the first
identified example of an enzyme system where ROS generation
was the primary function rather than a byproduct, as seen in mito-
chondria and other cell components. Phagocyte NADPH oxidase
function is best recognized in the respiratory (oxidative) burst
response, which is a key component of innate immunity (Quinn
and Gauss, 2004). Activation of phagocyte NADPH oxidase occurs
through a complex series of protein interactions (Figure 1). The
core catalytic component of NADPH oxidase, gp91phox, is stabi-
lized in the membrane by p22phox. Recruitment of the adaptor
protein p47phox facilitates addition to the complex of p40phox,
p67phox, and Rac (small GTP-binding protein), the later two appear
to regulate catalysis (Abo et al., 1991; Ando et al., 1992; Wientjes
et al., 1993; Heyworth et al., 1994; Hordijk, 2006; Orient et al., 2007;
Guichard et al., 2008; Sumimoto, 2008). Genome sequencing has
identified a family of NOX proteins that form distinct NADPH
oxidase complexes. Homologs of the core catalytic component
FIGURE 1 | Schematic representation of the protein components that
form the archetype phagocyte NADPH oxidase, NOX-2 contrasted to
NOX-1. Illustrated is the core catalytic component of phagocyte NADPH
oxidase, p91phox and, associated protein subunits required for a functional
enzyme (shown in green). The widely-expressed membrane associated
protein p22phox stabilizes the core catalytic component facilitating recruitment
of cytosolic adaptor proteins (p67phox, p47phox, p40phox) and small GTPase, Rac
(shown red). These are required for a functional oxidase. Superoxide (O•−2 ) is
generated via a one electron reduction of oxygen by NADPH. By analogy, the
functional NOX-1 enzyme consists of distinct protein subunits (shown in
purple) in a complex with p22phox (green) and Rac (red). NOX-1, the core
catalytic component, interacts with homologs of p47phox and p67phox called
NOXO1 (NOX Organizer Protein 1) and NOXA1 (NOX Activator Protein 1)
respectively.
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subunit of phagocyte NADPH oxidase have also been identified
(reviewed in Bedard and Krause, 2007, and termed NOX-1, -
3,-4,-5, DUOX1-2). Under this nomenclature the core catalytic
subunit of phagocyte NADPH oxidase (gp91phox) is termed NOX-
2. In the beta cell, expression of NOX-1, NOX-2, and NOX-4 has
been reported. With analogy to the phagocyte NADPH oxidase
(NOX-2), the functional unit for NOX-1 is also dependent upon its
association with cytosolic subunits. The subunits that bind NOX-
1 are NOXO1 (NOX organizer 1) and NOXA1 (NOX activator 1),
which while being distinct proteins are homologs of p47phox and
p67phox respectively (Banfi et al., 2003; Geiszt et al., 2003a; Takeya
et al., 2003; Cheng and Lambeth, 2004; Cheng et al., 2006). Recon-
stitution experiments have shown the functional unit for NOX-1
to require NOX-1/NOXO1/NOXA1 (Banfi et al., 2003; Geiszt et al.,
2003a; Takeya et al., 2003; Cheng and Lambeth, 2004). Binding of
p40phox or a homolog is not important for NOX-1 activity (Takeya
et al., 2003). NOX-4 activity does not appear to require associa-
tion with a NOX organizer/activator (Ambasta et al., 2004; Martyn
et al., 2006). However, NOX-1 and NOX-4 activity requires asso-
ciation with p22phox, which is widely-expressed in tissues (Cheng
et al., 2001), and Rac, which is expressed in beta cells, among other
tissues (reviewed in Kowluru, 2010). Inhibition of Rac activation
reduced oxidative stress mediated by high glucose and high FFA in
INS-1 cells (Subasinghe et al., 2011). Expression of NOXO1 and
NOXA1 has been reported in pancreas and beta cells (Uchizono
et al., 2006). Thus, stimuli which upregulate NADPH oxidase core
catalytic subunit expression in beta cells would be expected to
promote the formation of functional complexes and increase the
generation of ROS leading to cellular oxidative stress and/or ROS
mediated signal transduction. This was demonstrated to be true
for NOX-1. Recombinant overexpression of NOX-1 in NIH 3T3
cells resulted in elevated cellular ROS and induction of redox
signaling (Go et al., 2004).
ROLE OF NOX IN BETA CELL DYSFUNCTION
Role of NOX in beta cell dysfunction is supported by the obser-
vation that several NOX isoforms are expressed in pancreatic beta
cells including NOX-1, NOX-2, NOX-4, NOXO1, and NOXA1
(Oliveira et al., 2003; Nakayama et al., 2005; Lupi et al., 2006; Shao
et al., 2006; Uchizono et al., 2006). Diabetes relevant serum condi-
tions, including, increased pro-inflammatory cytokines, elevated
FFA (palmitate), or high glucose, induce NADPH oxidase expres-
sion (Morgan et al., 2007). Moreover, expression of NOX isoforms
are increased in animal models of type 2 diabetes (Nakayama et al.,
2005). Conversely, global inhibition of NADPH oxidase conferred
protection to beta cells exposed to cytokines or FFA (Michalska
et al., 2010). NADPH oxidase activity has been linked to regula-
tion of insulin secretion. Generation of ROS modulates glucose-
stimulated insulin secretion; having a positive effect upon acute
ROS activation but a negative effect upon chronic ROS activation
(Pi et al., 2007; Morgan et al., 2009) and reviewed in Goldstein et al.
(2005) and Newsholme et al. (2009). Global inhibition of NADPH
oxidase indicated NOX activity is necessary to initiate the transient
ROS increase required for glucose-stimulated insulin secretion.
However, specific roles of each NOX isoform remain to be eluci-
dated. This is, in part, due to a lack of isoform-specific inhibitors
(reviewed in Lambeth et al., 2008). NOX-2 activity in beta cells
has been reported linking transient ROS elevation to insulin
secretion, or association with mitochondrial dysregulation (Syed
et al., 2011a,b; Matti et al., 2012). Further, mice deficient in NOX-2
were protected against streptozotocin-induced beta cell destruc-
tion (Xiang et al., 2010). A pathological role for NOX-derived ROS
in beta cells is suggested with a linkage of NOX-2 activity in beta
cell dysfunction, induced by very low-density lipoprotein or free
fatty acid (Yuan et al., 2010; Jiao et al., 2012). Study of the contri-
bution of other NOX isoforms in beta cell function/dysfunction is
active. Targeting the relative contributions of NOX family mem-
bers has been approached in genetic depletion studies. Recent
study of mice genetically deficient in each of the NOX core catalytic
subunits has questioned the necessity of NOX for insulin secretion
in response to glucose stimulation. Individual deletion of NOX-
1, NOX-2, or NOX-4 did not abolish glucose-stimulated insulin
secretion as was seen (Li et al., 2012), and previously reported
(Uchizono et al., 2006), for the inhibitor of NOX activity dipheny-
lene iodonium (DPI). The resolution of this discrepancy lies in
the non-specific inhibitory action of DPI which, as a flavoenzyme
inhibitor, disrupts other flavin-dependent enzymes in addition to
NOX (Riganti et al., 2004). A caveat to the NOX-deletion approach
is that some degree of functional redundancy provided by the
remaining NOX is not eliminated, although compensatory upreg-
ulation of other NOXs in the targeted NOX deleted mice was not
observed (Li et al., 2012). This study by Li et al. provides focus on
basal NOX expression. An additional consideration is the upreg-
ulation of NOX enzymes in response to pathogenic stimuli. Study
has been made of the induced expression of NOX enzymes in islets
and beta cells following pro-inflammatory cytokine stimulation, a
condition that promotes beta cell dysfunction (Weaver et al., 2012).
As shown in Table 1, stimulation of human islets, mouse islets, or
murine beta cell lines with a pro-inflammatory cytokine cocktail
of TNFα, IL-1β, and IFNγ, preferentially induces the expression
of NOX-1. It is therefore possible that the activity of NOX-1 may
bean important component to beta cell pathogenesis. A decrease
in cytokine-induced NOX-1 expression was observed in geneti-
cally modified mice that had a co-associated enhanced glucose
tolerance and resistance to streptozotocin induced hyperglycemia
(Chang et al., 2010).
REGULATION OF NOX-1 EXPRESSION
Regulation of NOX-1 expression has been reported by a variety
of factors including angiotensin II (Suh et al., 1999; Lassegue
et al., 2001; Wingler et al., 2001; Katsuyama et al., 2002), inter-
feron (Geiszt et al., 2003b), the PKC activator PMA (Geiszt et al.,
Table 1 | Relative induction of NOX subunit expression in islets and
beta cells following stimulation with pro-inflammatory cytokines.
NOX-1 NOX-2 NOX-4 NOXA1 NOX01
Human islets +++ ± − ND ND
Mouse islets +++ + − ND ND
βTC-3 +++ ND ND ND ND
INS-1 +++ + − +++ −
ND, not determined.
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2003a; Takeya et al., 2003), and epidermal growth factor receptor
(EGFR) activation involving PI3K and PKC (Fan et al., 2005). The
promoter region for NOX-1 contains binding elements for AP-1,
NFκB, CREB, STATs, and Interferon (Kuwano et al., 2006). NOX-
1 expression is enhanced by IFNγ activation of STAT1 (Kuwano
et al., 2006) through binding of a γ-activated sequence (GAS)
element located −3818 to −3810 bp (Kuwano et al., 2006). Bind-
ing sites for GATA transcription factors are also present (Brewer
et al., 2006). Regulation of NOX-1 also is reported to involve
an autoregulatory feedback loop that promotes its own upreg-
ulation (Sancho and Fabregat, 2010). This feedback is mediated
through the upregulation of Src and ERK activity (Fan et al.,
2005; Adachi et al., 2008; Sancho and Fabregat, 2010). Induction
of NOX-1 in beta cells was recently linked to 12-lipoxygenase
activity (Weaver et al., 2012). Lipoxygenases catalyze the oxy-
genation of cellular polyunsaturated fatty acids to form lipid
inflammatory mediators. In the case of 12-lipoxygenase, arachi-
donic acid is converted to 12-hydroperoxyeicosatetraenoic acid
(12HPETE), which is subsequently reduced to the more stable
12-hydroxyeicosatetraenoic acid (12-HETE) by glutathione per-
oxidase (Yamamoto et al., 1997; Brash, 1999). The role of 12-LO
in inflammation, beta cells, and other physiologic and patho-
logic systems has been reviewed (Dobrian et al., 2011). With
regard beta cell dysfunction and diabetes, 12-lipoxygenase has
been established as a key mediator. Deletion of 12-LO in mice
confers resistant to diabetes induced by low dose streptozotocin
(Bleich et al., 1999) and blocks conversion to spontaneous dia-
betes in the NOD model of type 1 diabetes (McDuffie et al., 2008).
A product of 12-LO activity, 12-HETE, has been reported in rat
islets (Metz et al., 1983; Metz, 1985; Turk et al., 1985; Shannon
et al., 1992; Kawajiri et al., 2000; Prasad et al., 2003), human
islets (Chen et al., 2005; Persaud et al., 2007; Ma et al., 2010),
and rodent beta cell lines (Bleich et al., 1995; Chen et al., 2005).
Overexpression of 12-LO in beta cells leads to loss of function
and activation of apoptosis (Prasad et al., 2003). Further, direct
addition of 12-HETE impairs insulin secretion from beta cells,
and can induce apoptosis (Chen et al., 2005). Pro-inflammatory
cytokines induce 12-LO activity in islets and beta-cell lines (Ble-
ich et al., 1995; Chen et al., 2005). Direct addition of 12-HETE or
pro-inflammatory cytokines to beta cells induced NOX-1 expres-
sion (Weaver et al., 2012). Furthermore, inhibition of 12-LO
activity, with selective small molecules (Kenyon et al., 2011),
blocked the induction of NOX-1 by pro-inflammatory cytokines
(Weaver et al., 2012). These data indicate an integration of pro-
inflammatory cytokine stimulation and activation of 12-LO in the
upregulation of NOX-1 in beta cells; a pathway linked to beta cell
dysfunction.
REDOX SIGNALING
Redox signaling is a functional consequence of NOX upregulation.
Over expression of NOX-1 in NIH 3T3 cells results in an upreg-
ulation of cellular ROS (Go et al., 2004). The capacity of NOX to
elevate ROS production in beta cells has strikingly been reported
to equal levels found in neutrophils (Oliveira et al., 2003). Both
rat neutrophils and rat beta cells reach similar maximum levels
of superoxide and H2O2 in response to a glucose challenge, albeit
with different kinetics, 50% Vmax occurring at 5 and 45 min in
neutrophils and beta cells respectively (Oliveira et al., 2003). While
elevated cellular ROS readily brings to mind concepts of oxidative
stress and a deleterious oxidizing environment, designed signal-
ing cascades of oxidation-sensitive second messenger targets also
result. Unlike the ROS products that result from several metabolic
processes, the cellular function of NOX enzymes is to generate
ROS. This suggests the option that target-specific signaling path-
ways may be regulated by low levels of ROS; distinct from a global
generalized oxidative environment. Several signaling pathways are
linked to a ROS-mediate regulation (reviewed in Goldstein et al.,
2005; Mittler et al., 2011). These include activation of kinases in
the mitogen activated protein (MAP) Kinase family and Src-kinase
(Giannoni et al., 2005). Over expression of NOX-1 resulted in a
concomitant activation of the MAP kinases, JNK, and ERK1/2
(Go et al., 2004). Other second messengers activated by NOX-1
include p38MAPK and AKT (Sancho and Fabregat, 2010). Thus,
elevated expression of NOX-1, as occurs in beta cells upon expo-
sure to elevated pro-inflammatory cytokines (Weaver et al., 2012),
results in increased ROS expression that could induce discrete
second messenger signaling, global destructive oxidative stress,
or both.
REGULATION OF NOX-1 EXPRESSION BY ROS-INDUCED
SECOND MESSENGERS
Regulation of NOX-1 expression by ROS-induced second mes-
sengers has been proposed in the liver cell line FaO (Sancho and
Fabregat, 2010). These data suggest a positive feed-forward reg-
ulation of NOX-1. In beta cells, which have a low anti-oxidant
capacity relative to metabolic activity, a feed-forward control of
ROS production could rapidly result in a pathological state. Con-
sequently, identifying and inhibiting such regulation could prove
important in developing new strategies for preservation and pro-
tection of functional beta cell mass in diabetes. Studies have been
performed to address if regulation of NOX-1 in beta cells is sub-
ject to feed-forward control (Weaver and Taylor-Fishwick, 2013).
A summary of the approach used is shown in Figure 2. These
studies have driven the proposed model that while NOX-1 is
induced by pro-inflammatory cytokine stimulation in beta cells,
a component of NOX-1 expression derives from a self-sustained
upregulation mediated by elevated ROS expression and second
messengers. The first clue for a feed-forward regulation of NOX-
1 in beta cells stemmed from the observation that the induced
expression of NOX-1 in pro-inflammatory cytokine-stimulated
beta cells was abrogated with inhibitors of NADPH oxidase activ-
ity. Since NOX activity is subsequent to induced gene expression,
the simplest explanation of the data is that NOX activity upreg-
ulates NOX-1 gene expression, a feed-forward control. NOX-1
induction of ROS was further implicated. Addition of general
anti-oxidants, which neutralize cellular ROS, inhibited NOX-1
expression induced from pro-inflammatory cytokine stimulation.
Moreover pro-oxidants, that directly elevate cellular ROS in the
absence of other stimuli, induced NOX-1 expression. The redox
sensitive kinase Src-kinase was shown to be activated by ROS in
this pathway and a selective inhibitor of Src-kinase, PP2, disrupted
stimuli-induced NOX-1 expression. The disruption in NOX-1 was
not observed with the inactive structural analog, PP3. Importantly,
inhibitors of these resolved signaling pathways also protected beta
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FIGURE 2 | Feed-forward regulation of NOX-1 expression in beta cells.
(A) Experimental approach to demonstrate a feed-forward regulation of
NOX-1 in beta cells that involves NOX activity and cellular redox state.
Inhibition of NADPH oxidase activity (purple box) with either a selective
NOX-1/4 pyrazolopyridine dione inhibitor (PPD) or general inhibitors
apocynin (Apo), diphenylene iodonium (DPI) blocks NOX-1 gene and protein
expression initiated by pro-inflammatory cytokine (PIC) stimulation. This
suggests NADPH oxidase activity regulates NOX-1 expression.
Neutralization of ROS with general anti-oxidants (green box)
glutathione-ethyl ester (GEE) or butylated hydroxyanisole (BHA) inhibited
PIC-stimulated NOX-1. Conversely, direct elevation of ROS with
pro-oxidants (red box) hydrogen peroxide (H2O2) or pyocyanin, upregulated
NOX-1 expression. This places ROS elevation in a pathway regulating
NOX-1 expression. Interruption of Src-kinase signaling with inhibitor PP2
blocked NOX-1 expression induced by pro-oxidant or PIC-stimulation.
Interruption was not observed using the control (inactive) compound PP3.
This indicates that activation of Src-kinase signaling that leads to NOX-1
gene transcription is a consequence of elevated ROS. Beta cell dysfunction,
as measured by increase in apoptosis and loss of
glucose-stimulated-insulin-secretion (GSIS), follows sustained elevation of
ROS. (B) Candidate effectors of Src-kinase activation are shown along with
selective inhibitors (italics), which are available to map key contributing
pathways. In terms of disease pathology, self-sustaining NOX-1 would lead
to unbridled ROS generation, oxidative stress, and induce beta cell
dysfunction/destruction. Consequently, this pathway has potential for high
impact therapeutic intervention.
cells from the damaging effects induced by pro-inflammatory
cytokine stimulation (Weaver and Taylor-Fishwick, 2013). Pro-
inflammatory cytokine simulation of beta cells leads to increased
expression of MCP-1, loss of glucose-stimulated insulin secretion,
and induction or apoptosis. These three readouts of beta cell func-
tion were preserved by disruption of the NOX-1 feed-forward
regulation.
CHEMICAL INHIBITION OF NADPH OXIDASE ACTIVITY
Chemical inhibition of NADPH oxidase activity is an active area
of investigation. Historically accepted inhibitors of NADPH oxi-
dase activity, such as apocynin and DPI have been acknowl-
edged as contributing to misleading interpretations due to
low enzyme selectivity (Riganti et al., 2004; Vejrazka et al.,
2005; Heumuller et al., 2008; Castor et al., 2010). Apocynin
(4′-hydroxy-3′methoxyacetophenone) is a naturally occurring
methoxy-substituted catechol. First identified in the 1800s, apoc-
ynin was recognized, accepted, and widely used as a selective
NADPH oxidase inhibitor from mid 1990. Though apocynin
continues to be used and marketed as an inhibitor of NADPH
oxidase, it is not considered selective for NOX subunits. Apocynin
is a pro-drug activated by peroxidase, its specificity of action is
questioned following reports of activity in peroxide-deficient cells.
Further, apocynin stimulated ROS production in non-phagocytes
(Vejrazka et al., 2005) and demonstrated anti-oxidant effects in
endothelial and vascular smooth muscle cells (Heumuller et al.,
2008). Likewise, DPI has been extensively described in research
literature as a NADPH oxidase inhibitor. DPI inhibits electron
transporters. As an inhibitor of flavoenzymes, DPI interrupts
NADPH oxidase activity but also other flavin-dependent enzymes
(Riganti et al., 2004). Thus, DPI is not a selective NADPH oxi-
dase inhibitor. Reflective of the significant interest in NADPH
oxidases and disease pathology, aggressive investigation for new
and selective small molecular weight inhibitors of NOX sub-
units is ongoing (reviewed in Lambeth et al., 2008; Jaquet et al.,
2009; Cifuentes-Pagano et al., 2012). With regards NOX-1, high
throughput screen approaches have identified two compound
series with selectivity over NOX-2 activity. Several pyrazolopy-
ridine dione inhibitors with nanomolar potency to NOX-1 and
NOX-4 have been described that exhibit ten-fold selectivity over
NOX-2 inhibition (Laleu et al., 2010). The lead compound in
this series, GKT 136901 is orally bioavailable. A second approach
has identified an active phenothiazine (2-acetylphenothiazine,
ML171) with nanomolar IC50 and 20-fold selectivity over NOX-
2, and NOX-4 (Gianni et al., 2010). These compounds provide
promise to explore the role of NOX subunits in disease pathology
and assessment of their inhibition as new therapeutic approaches
to disease.
In summary, the free-radical generating enzymes NADPH oxi-
dases may prove to have a greater importance than previously
recognized in pathogenic stimuli resulting in beta cell dysfunc-
tion. This is reflected by evidence of a feed-forward regulation of
NOX-1 expression that could result in a self-sustaining and esca-
lating cellular ROS expression, a potentially pathological state for
which the beta cell is poorly prepared to rectify. While a newly
emerging field, confidence in the contribution of NOX-1 to beta
cell dysfunction will be achieved by pathway resolution. Selec-
tive chemical inhibition of NOX-1 and description of the second
messenger events that mediate ROS induction of NOX-1 in beta
cells will facilitate pathway resolution. Candidate messengers and
their inhibitors are shown in Figure 2B. Targeted disruption of
a feed-forward regulation of NOX-1 in beta cells holds promise
to help preserve and protect functional beta cell mass in diabetes.
Clearly, old-generation inhibitors that have been proven to exhibit
low specificity have resulted in missteps.
NOX, NOX
Who’s there?
Snaf
. . ..?
Future development of safe, highly characterized, and selective
NOX inhibitors is required. Considerable research is being directed
at this aim and with the benefit of hindsight, a promise of future
targets for new therapeutic strategies is anticipated.
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